Visceral fat area predicts survival in @entity1 with XXXX treated with @entity4149 kinase inhibitors.

@entity1 @entity46821 @entity137 @entity2857 @entity6288 @entity8566 @entity157 @entity4149
BACKGROUND: Anthropometric measurements have been linked to resistance to anti-angiogenic treatment and survival. METHODS: @entity1 with @entity157 treated with @entity2857 or @entity46821 in 2008-2011 were included in this retrospective study. Anthropometric measurements were assessed using computed tomography and were correlated with @entity137 , radiological response, and overall survival. RESULTS: 52 @entity1 were included, Barcelona Clinic Liver Classification B (38%) and C (62%), with a mean value of a-fetoprotein of 29,554  85,654ng/mL, with a median overall survival of 10.5 months. @entity6288 was associated with a greater rate of @entity8566 (P=0.049). Modified Response Evaluation Criteria In Solid Tumours (mRECIST) and Choi criteria were significantly associated with survival, but RECIST criteria were not. An absence of @entity8566 and high-visceral fat area were associated with progressive disease as assessed by RECIST and mRECIST criteria. In multivariate analyses, high visceral fat area (HR=3.6; P=0.002), low lean body mass (HR=2.4; P=0.015), and presence of @entity8566 (HR=1.8; P=0.004) were significantly associated with overall survival. In time-dependent multivariate analyses; only high visceral fat area was associated with survival. CONCLUSION: Visceral fat area is associated with survival and seems to be a predictive marker for primary resistance to @entity4149 kinase inhibitors in @entity1 with @entity157 .
